Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)

J Endocrinol Invest. 2016 Jan;39(1):103-21. doi: 10.1007/s40618-015-0349-9. Epub 2015 Jul 14.

A Stigliano¹, I Chiodini², R Giordano^{3

4}, A Faggiano⁵, L Canu⁶, S Della Casa⁷, P Loli⁸, M Luconi⁶, F Mantero⁹, M Terzolo¹⁰

¹ Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy. [email protected].
² Endocrinology and Metabolic Disease Unit, IRCCS Foundation Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
³ Department of Clinical and Biological Science, University of Turin, Turin, Italy.
⁴ Division of Endocrinology, Diabetology and Metabolism, Department of Medical Science, University of Turin, Turin, Italy.
⁵ Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
⁶ Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
⁷ Endocrinology, Department of Internal Medicine, Catholic University of Rome, Rome, Italy.
⁸ Endocrine Unit, Niguarda Cà Granda Hospital, Milan, Italy.
⁹ Endocrinology Unit, Department of Medicine-DIMED, University of Padua, Padua, Italy.
¹⁰ Internal Medicine I, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

No abstract available

Keywords: Adjuvant treatment; Adrenocortical carcinoma; Mitotane; Overall survival; Prognostic factors; Recurrence-free survival.

Publication types